Experienced in Necrotizing Vasculitis

Dr. Joseph Z. Forstot

Rheumatology
Pardo Forstot Baca And Alboukrek PA
5162 Linton Blvd, Suite 101, 
Delray Beach, FL 
Accepting New Patients
Experienced in Necrotizing Vasculitis
Pardo Forstot Baca And Alboukrek PA
5162 Linton Blvd, Suite 101, 
Delray Beach, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Forstot is a Rheumatologist in Delray Beach, Florida. Dr. Forstot is rated as an Experienced provider by MediFind in the treatment of Necrotizing Vasculitis. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Rheumatoid Arthritis (RA), and Calcium Pyrophosphate Arthritis. Dr. Forstot is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in FL
Hospital Affiliations
Boca Raton Regional Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

PARDO FORSTOT BACA AND ALBOUKREK PA
5162 Linton Blvd, Suite 101, Delray Beach, FL 33484
Other Locations
PARDO FORSTOT BACA AND ALBOUKREK PA
800 Meadows Rd, Boca Raton, FL 33486

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 5 Less Clinical Trials

2 Total Publications

Exploring the antiquity of rheumatoid arthritis: A case study from medieval Transylvania.
Exploring the antiquity of rheumatoid arthritis: A case study from medieval Transylvania.
Journal: International journal of paleopathology
Published: May 24, 2024
Similar Doctors
John Donohue
Distinguished in Necrotizing Vasculitis
Dr. John Donohue
Rheumatology
Distinguished in Necrotizing Vasculitis
Dr. John Donohue
Rheumatology

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (28.8 miles away)
877-463-2010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Donohue is a Rheumatologist in Weston, Florida. Dr. Donohue is rated as a Distinguished provider by MediFind in the treatment of Necrotizing Vasculitis. His top areas of expertise are Mixed Connective Tissue Disease, MASS Phenotype, Necrotizing Vasculitis, and Giant Cell Arteritis (GCA).

Advanced in Necrotizing Vasculitis
Dr. Richard S. Glick
Rheumatology
Advanced in Necrotizing Vasculitis
Dr. Richard S. Glick
Rheumatology
6405 N Federal Hwy, Suite 105, 
Fort Lauderdale, FL 
 (16.0 miles away)
954-772-3660
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Richard Glick is a Rheumatologist in Fort Lauderdale, Florida. Dr. Glick is rated as a Distinguished provider by MediFind in the treatment of Necrotizing Vasculitis. His top areas of expertise are Mixed Connective Tissue Disease, MASS Phenotype, Necrotizing Vasculitis, and Rheumatoid Arthritis (RA). Dr. Glick is currently accepting new patients.

Advanced in Necrotizing Vasculitis
Dr. Darrell N. Fiske
Rheumatology
Advanced in Necrotizing Vasculitis
Dr. Darrell N. Fiske
Rheumatology

Rheumatology Associates PA

2220 Se Ocean Blvd, Suite 101, 
Stuart, FL 
 (52.7 miles away)
772-283-8380
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Darrell Fiske is a Rheumatologist in Stuart, Florida. Dr. Fiske is rated as a Distinguished provider by MediFind in the treatment of Necrotizing Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Rhizomelic Pseudopolyarthritis. Dr. Fiske is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Forstot's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile